The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: An Italian healthcare payer perspective

被引：0
|
作者：
Patterson, K. [1 ]
Bhattacharyya, S. [1 ]
Personeni, N. [2 ]
Gebbia, V. [3 ]
Novelli, P. [4 ]
Di Matteo, S. [5 ]
Colombo, G. [6 ]
Pescott, C. [7 ]
机构：
[1] BresMed, Hlth Econ, Sheffield, S Yorkshire, England
[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[3] Univ Palermo, La Maddalena Hosp, Palermo, Italy
[4] Merck Serono SpA, HTA & Market Access, Rome, Italy
[5] SAVE Studi Anal Valutaz Econ srl, Hlth Econ & Outcomes Res, Milan, Italy
[6] Univ Pavia, Dept Drug Sci, Pavia, Italy
[7] Merck Healthcare KGaA, Global Evidence & Value Dev, Darmstadt, Germany
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
596P
引用
收藏
页码：225 / 225
页数：1
相关论文
共 50 条
  • [1] Adverse event management costs for first-line treatment with cetuximab or panitumumab of RAS wild-type metastatic colorectal cancer patients in Latin America
    Pescott, Chris
    Kasle, Adam
    Esteso, Federico
    Stefani, Stephen
    Brust, Leandro
    Pinto, Jose
    Tilli, Malena
    Massello, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Fakih, Marwan G.
    Knox, Hediyyih N.
    Maglinte, Gregory A.
    Hjelmgren, Jonas
    Barber, Beth
    Schwartzberg, Lee S.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (08) : 619 - 628
  • [3] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Irina A. Tikhonova
    Nicola Huxley
    Tristan Snowsill
    Louise Crathorne
    Jo Varley-Campbell
    Mark Napier
    Martin Hoyle
    PharmacoEconomics, 2018, 36 : 837 - 851
  • [4] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Tikhonova, Irina A.
    Huxley, Nicola
    Snowsill, Tristan
    Crathorne, Louise
    Varley-Campbell, Jo
    Napier, Mark
    Hoyle, Martin
    PHARMACOECONOMICS, 2018, 36 (07) : 837 - 851
  • [5] COST-MINIMIZATION ANALYSIS OF PANITUMUMAB COMPARED WITH CETUXIMAB IN THE FIRST-LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL
    dos Santos, R. F.
    Riveros, B. S.
    Nita, M. E.
    Pedro, G. O.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A739
  • [6] Costs of adverse event management associated with first-line cetuximab or panitumumab in patients with metastatic colorectal cancer in Spain.
    Grana Suarez, Begona
    Tarazona, Noelia
    Duran Moran, Olga
    Fernandez Gonzalez, Ana
    De los Santos Real, Heidi
    Pescott, Chris P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 83 - 83
  • [7] Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy
    Yamaguchi, Kensei
    Ando, Masahiko
    Ooki, Akira
    Beier, Frank
    Guenther, Silke
    von Hohnhorst, Philipp
    Van Cutsem, Eric
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E29 - E37
  • [8] Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
    Patel, Shiven B.
    Gill, David
    Garrido-Laguna, Ignacio
    ONCOTARGETS AND THERAPY, 2016, 9 : 75 - 86
  • [9] Cost-Effectiveness Analysis of Panitumumab Compared with Bevacizumab for First-Line Treatment of Patients with Wild-Type RAS Metastatic Colorectal Cancer in Germany
    Frank, M.
    Lange, A.
    Michailov, G.
    Lebioda, A.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2016, 21 (04): : 203 - 209
  • [10] Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients
    Samalin, Emmanuelle
    Mazard, Thibault
    Assenat, Eric
    Rouyer, Magali
    de la Fouchardiere, Christelle
    Guimbaud, Rosine
    Smith, Denis
    Portales, Fabienne
    Ychou, Marc
    Adenis, Antoine
    Fiess, Catherine
    Lopez-Crapez, Evelyne
    Thezenas, Simon
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1375 - 1381
12345